ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 222 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $44,624,178 | -14.0% | 967,357 | -25.3% | 0.01% | -15.4% |
| Q1 2023 | $51,911,856 | -13.4% | 1,294,560 | 0.0% | 0.01% | -18.8% |
| Q4 2022 | $59,976,965 | -57.3% | 1,294,560 | -61.8% | 0.02% | -61.0% |
| Q3 2022 | $140,425,000 | -31.0% | 3,391,082 | -0.6% | 0.04% | -25.5% |
| Q2 2022 | $203,596,000 | -16.2% | 3,412,406 | +2.0% | 0.06% | 0.0% |
| Q1 2022 | $242,891,000 | -46.2% | 3,345,026 | -37.7% | 0.06% | -42.1% |
| Q4 2021 | $451,547,000 | -11.6% | 5,369,774 | -5.2% | 0.10% | -18.8% |
| Q3 2021 | $510,875,000 | -1.8% | 5,665,193 | +3.8% | 0.12% | -1.7% |
| Q2 2021 | $520,349,000 | -15.7% | 5,457,124 | +0.6% | 0.12% | -23.7% |
| Q1 2021 | $617,570,000 | -28.8% | 5,424,122 | -13.4% | 0.16% | -34.2% |
| Q4 2020 | $866,806,000 | +70.2% | 6,261,306 | +1.0% | 0.24% | +51.0% |
| Q3 2020 | $509,422,000 | +7.0% | 6,197,949 | +1.9% | 0.16% | +0.6% |
| Q2 2020 | $475,979,000 | +74.7% | 6,085,132 | -0.8% | 0.16% | +40.5% |
| Q1 2020 | $272,453,000 | +5.6% | 6,132,194 | +1.5% | 0.11% | +26.1% |
| Q4 2019 | $258,078,000 | +0.4% | 6,042,575 | +0.6% | 0.09% | -10.2% |
| Q3 2019 | $257,055,000 | -28.0% | 6,008,757 | +6.9% | 0.10% | -31.0% |
| Q2 2019 | $356,779,000 | -7.6% | 5,618,562 | +0.9% | 0.14% | -14.5% |
| Q1 2019 | $386,235,000 | +93.5% | 5,568,549 | +21.3% | 0.17% | +67.7% |
| Q4 2018 | $199,567,000 | -40.0% | 4,589,854 | +5.3% | 0.10% | -34.9% |
| Q3 2018 | $332,834,000 | +20.1% | 4,359,891 | +20.9% | 0.15% | -51.4% |
| Q2 2018 | $277,098,000 | +51.3% | 3,604,764 | +0.4% | 0.31% | +47.6% |
| Q1 2018 | $183,107,000 | +10.3% | 3,591,046 | +0.3% | 0.21% | +12.8% |
| Q4 2017 | $165,984,000 | +7.6% | 3,578,787 | +23.6% | 0.19% | +1.6% |
| Q3 2017 | $154,213,000 | +4.5% | 2,895,481 | +21.9% | 0.18% | -6.1% |
| Q2 2017 | $147,510,000 | -0.0% | 2,374,985 | +9.1% | 0.20% | -1.5% |
| Q1 2017 | $147,539,000 | +109.7% | 2,176,733 | +117.5% | 0.20% | +96.1% |
| Q4 2016 | $70,370,000 | +106.5% | 1,000,854 | +108.4% | 0.10% | +108.2% |
| Q3 2016 | $34,072,000 | – | 480,300 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |